Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fazirsiran - Arrowhead Pharmaceuticals/Takeda Pharmaceuticals USA

Next Previous
Search
Drug Profile

Fazirsiran - Arrowhead Pharmaceuticals/Takeda Pharmaceuticals USA

Alternative Names: ADS-001; ARO-AAT; Fazirsiran sodium - Arrowhead Pharmaceuticals/Takeda Pharmaceuticals USA; TAK-999

Latest Information Update: 28 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arrowhead Pharmaceuticals
  • Developer Arrowhead Pharmaceuticals; Takeda
  • Class Anti-inflammatories; Hepatoprotectants; Oligonucleotides; Small interfering RNA
  • Mechanism of Action Alpha 1-antitrypsin expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alpha 1-antitrypsin deficiency

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for phase-I development in Alpha-1-antitrypsin-deficiency(In volunteers) in New Zealand (SC, Injection)
  • 06 Mar 2024 Takeda initiates a phase-III trial in Alpha 1-antitrypsin deficiency in Austria, Germany, Italy, Poland, Portugal, and the United Kingdom (SC) (NCT05677971) (EudraCT2022-501943-34)
  • 01 Mar 2024 Phase-III clinical trials in Alpha 1-antitrypsin deficiency in Italy, Poland, Portugal (SC) (NCT06165341) (EudraCT2023-504198-19)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top